Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Carcinoma; Pituitary adenoma; Pituitary cancer; Pituitary tumours
- Focus Therapeutic Use
Most Recent Events
- 03 Jul 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 03 Jul 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
- 29 Jun 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.